Wall Street Zen Upgrades Merck After Cancer Therapy Trial Success

Merck & Co., Inc. (NYSE:MRK) has been upgraded to 'buy' by equities researchers at Wall Street Zen, following a successful Phase 3 trial for its personalized cancer therapy.

The treatment, developed in partnership with Moderna, met key goals of improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. This marks the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications.

In other news, several Wall Street firms have raised their outlooks for MRK, with Goldman Sachs increasing its price target to $160 and keeping a 'buy' rating. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.